Shots:
- Senti Bio to receive up front and funding to support its research activities. If Spark exercises the option, Senti Bio will be eligible to receive an option exercise payment, development, regulatory, and sales milestone along with royalties per product which may exceed $645M
- Senti Bio will lead designing, building, and testing cell type and disease specific-synthetic promoters for use in CNS, ocular or liver-directed gene therapies
- Spark to get an option to exclusively license synthetic promoters emerges from collaboration to develop gene therapy products in the specified indications. Upon option exercise, Spark will lead pre/ clinical, and commercialization activities for gene therapy candidates incorporating Senti Bio’s licensed synthetic promoters
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Fierce Biotech
The post Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies first appeared on PharmaShots.
